Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George Painter

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Science (New York, N.Y.)|December 10, 2016
Arrested developmentGeorge Painter
ACS Medicinal Chemistry Letters|June 6, 2014
Evolving therapies for the treatment of HCV viral hepatitisGeorge Painter
ACS Medicinal Chemistry Letters|May 26, 2018
Academic Drug Development: The DRIVE ModelDennis Liotta, George Painter
Viruses|October 14, 2011
Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeuticsScott Parker, Akbar M Siddiqui, George Painter, et al.
Antimicrobial Agents and Chemotherapy|March 7, 2012
First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA virusesWendy Painter, Alice Robertson, Lawrence C Trost, et al.
Trials|August 24, 2021
Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2Wendy Holman, Wayne Holman, Stacy McIntosh, et al.
Antimicrobial Agents and Chemotherapy|August 17, 2002
Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitroWilliam E Delaney, Ros Edwards, Danni Colledge, et al.
Antiviral Therapy|December 3, 2008
Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001Scott Parker, Jill Schriewer, Christina Oberle, et al.
The Journal of Infectious Diseases|July 12, 2021
Letter to the Editor in Response to Zhou et alSean Troth, Joan Butterton, Carisa Stadlman DeAnda, et al.
Viruses|March 4, 2011
Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humansAmanda D Rice, Mathew M Adams, Bernhard Lampert, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Science (New York, N.Y.)|December 10, 2016
Arrested developmentGeorge Painter
ACS Medicinal Chemistry Letters|June 6, 2014
Evolving therapies for the treatment of HCV viral hepatitisGeorge Painter
ACS Medicinal Chemistry Letters|May 26, 2018
Academic Drug Development: The DRIVE ModelDennis Liotta, George Painter
Viruses|October 14, 2011
Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeuticsScott Parker, Akbar M Siddiqui, George Painter, et al.
Antimicrobial Agents and Chemotherapy|March 7, 2012
First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA virusesWendy Painter, Alice Robertson, Lawrence C Trost, et al.
Trials|August 24, 2021
Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2Wendy Holman, Wayne Holman, Stacy McIntosh, et al.
Antimicrobial Agents and Chemotherapy|August 17, 2002
Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitroWilliam E Delaney, Ros Edwards, Danni Colledge, et al.
Antiviral Therapy|December 3, 2008
Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001Scott Parker, Jill Schriewer, Christina Oberle, et al.
The Journal of Infectious Diseases|July 12, 2021
Letter to the Editor in Response to Zhou et alSean Troth, Joan Butterton, Carisa Stadlman DeAnda, et al.
Viruses|March 4, 2011
Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humansAmanda D Rice, Mathew M Adams, Bernhard Lampert, et al.
Pageof 3